Marc Evans

7.5k total citations · 2 hit papers
183 papers, 5.5k citations indexed

About

Marc Evans is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Marc Evans has authored 183 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 140 papers in Endocrinology, Diabetes and Metabolism, 43 papers in Surgery and 40 papers in Molecular Biology. Recurrent topics in Marc Evans's work include Diabetes Treatment and Management (106 papers), Diabetes Management and Research (72 papers) and Metabolism, Diabetes, and Cancer (38 papers). Marc Evans is often cited by papers focused on Diabetes Treatment and Management (106 papers), Diabetes Management and Research (72 papers) and Metabolism, Diabetes, and Cancer (38 papers). Marc Evans collaborates with scholars based in United Kingdom, United States and Denmark. Marc Evans's co-authors include Craig J. Currie, Chris D. Poole, David M. Williams, John R. Peters, Phil McEwan, Christopher Ll. Morgan, Asif Nawaz, Aodán Tynan, Oswaldo L. Bracco and Robert J. Heine and has published in prestigious journals such as The Lancet, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Marc Evans

174 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study

2010 615 citations Craig J. Currie, John R. Peters et al. The Lancet profile →
A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives

2021 149 citations Marc Evans, Angharad R. Morgan et al. Advances in Therapy profile →

Peers

Countries citing papers authored by Marc Evans

Since Specialization

Citations

This map shows the geographic impact of Marc Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Evans more than expected).

Fields of papers citing papers by Marc Evans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Evans. The network helps show where Marc Evans may publish in the future.

Co-authorship network of co-authors of Marc Evans

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Evans. A scholar is included among the top collaborators of Marc Evans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Evans. Marc Evans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model 2025 ·Diabetes Obesity and Metabolism ·Phil McEwan, V. Foos, Geraint Roberts, Robert L. Jenkins, Marc Evans, David C. Wheeler, Jieling Chen	1
2	Analysis of Tirzepatide Acquisition Costs and Weight Reduction Outcomes in the United Kingdom: Insights from the SURMOUNT-1 Study 2025 ·Advances in Therapy ·Marc Evans, (unknown), (unknown), Laurienne Edgar, Erik Spaepen, (unknown)	2
3	The associations between multimorbidity, healthcare resource utilisation and costs in individuals with Alzheimer's disease dementia 2025 ·SHILAP Revista de lepidopterología ·Sophie Edwards, Marc Evans, Craig Ritchie, (unknown), (unknown), Benjamin Bray, A. J. Clark, (unknown), Dominic Trépel	0
4	Real world outcomes, healthcare utilisation and costs of Alzheimer's disease in England 2024 ·SHILAP Revista de lepidopterología ·Sophie Edwards, Dominic Trépel, Craig Ritchie, (unknown), Danielle E Robinson, (unknown), Benjamin Bray, A. J. Clark, Milana Ivkovic, (unknown), (unknown), Marc Evans	3
5	Comparison of the impact of type 1 and type 2 diabetes on quality of life of families of patients: A UK cross‐sectional study 2024 ·Diabetes Obesity and Metabolism ·(unknown), A.Y. Finlay, Faraz M Ali, Kennedy Otwombe, S J Nixon, Lindsay George, Marc Evans, John R Ingram, Sam Salek	1
6	The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus 2022 ·Age and Ageing ·Marc Evans, Angharad R. Morgan, Sarah Davies, (unknown), W. David Strain	24
7	The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes 2022 ·Diabetes Obesity and Metabolism ·Marc Evans, (unknown), (unknown), (unknown), (unknown), Barnaby Hunt, Stephen C. Bain	5
8	Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK : A long‐term cost‐effectiveness analysis based on SUSTAIN 11 2022 ·Diabetes Obesity and Metabolism ·Marc Evans, Barrie Chubb, Samuel J. P. Malkin, (unknown), Jack Lawson, Barnaby Hunt	6
9	An Indirect Comparison of Basal Insulin Plus Once-Weekly Semaglutide and Fully Optimised Basal–Bolus Insulin in Type 2 Diabetes 2022 ·Diabetes Therapy ·Ildiko Lingvay, Andrei‐Mircea Catarig, Jack Lawson, Barrie Chubb, Anders Gorst‐Rasmussen, Marc Evans	1
10	The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes 2021 ·Diabetes Therapy ·W. David Strain, Angharad R. Morgan, Marc Evans	3
11	Vaccinating Adolescents and Children Significantly Reduces COVID-19 Morbidity and Mortality across All Ages: A Population-Based Modeling Study Using the UK as an Example 2021 ·Vaccines ·Tinevimbo Shiri, Marc Evans, Carla Talarico, Angharad R. Morgan, (unknown), Philip O. Buck, Phil McEwan, W. David Strain	16
12	Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes 2020 ·Drugs ·Stewart B. Harris, Martin J. Abrahamson, Antonio Ceriello, G. Charpentier, Marc Evans, Roger Lehmann, Andreas Liebl, Sultan Linjawi, Richard I. G. Holt, Nóra Hosszúfalusi, Guy E.H.M. Rutten, Tina Vilsbøll	17
13	Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK 2019 ·Diabetic Medicine ·Stephen C. Bain, Ameet Bakhai, Marc Evans, (unknown), Ian Menown, W. David Strain	4
14	SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice 2019 ·Diabetes Therapy ·(unknown), Steve Baín, Debbie Hicks, (unknown), Dipesh Patel, Marc Evans, (unknown), (unknown), Nicola Milne, Adie Viljoen, John Wilding	37
15	Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study 2018 ·BMJ Open Diabetes Research & Care ·Jason Gordon, Phil McEwan, Iskandar Idris, Marc Evans, Jorge Puelles	40
16	The impact of treatment non-compliance on mortality in people with type 1 diabetes 2012 ·Journal of Diabetes and its Complications ·Craig J. Currie, Mark Peyrot, Christopher Ll. Morgan, Chris D. Poole, Sara Jenkins‐Jones, Richard R. Rubin, Christopher M. Burton, Marc Evans	49
17	The Impact of Treatment Noncompliance on Mortality in People With Type 2 Diabetes 2012 ·Diabetes Care ·Craig J. Currie, Mark Peyrot, Christopher Ll. Morgan, Chris D. Poole, Sara Jenkins‐Jones, Richard R. Rubin, Christopher M. Burton, Marc Evans	205
18	Total lipid management and residual risk: beyond statin therapy 2011 ·British Journal of Hospital Medicine ·Marc Evans	2
19	Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study breakdown → 2010 ·The Lancet ·Craig J. Currie, John R. Peters, Aodán Tynan, Marc Evans, Robert J. Heine, Oswaldo L. Bracco, (unknown), Chris D. Poole	615
20	Preputial reconstruction for phimosis and infantile penis 1977 ·Journal of the American Animal Hospital Association ·(unknown), D. W. DeYoung, Marc Evans	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact